1. bookVolume 32 (2019): Edition 1 (March 2019)
Détails du magazine
License
Format
Magazine
eISSN
2300-6676
ISSN
2084-980X
Première parution
30 May 2014
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Effect of tirapazamine on selected kidney parameters in rats treated with cisplatin

Publié en ligne: 06 Apr 2019
Volume & Edition: Volume 32 (2019) - Edition 1 (March 2019)
Pages: 18 - 22
Reçu: 19 Mar 2018
Accepté: 28 May 2018
Détails du magazine
License
Format
Magazine
eISSN
2300-6676
ISSN
2084-980X
Première parution
30 May 2014
Périodicité
4 fois par an
Langues
Anglais

1. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99: 1441-54.10.1093/jnci/djm13517895480Search in Google Scholar

2. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol. 1999;43:213-20.10.1007/s0028000508869923551Search in Google Scholar

3. Rischin D, Peters L, Fisher R. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.10.1200/JCO.2005.01.07215625362Search in Google Scholar

4. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys. 2007;69:560-71.10.1016/j.ijrobp.2007.05.04917869669Search in Google Scholar

5. Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol. 2006;1:71-9.10.2174/15748840677526819218666379Search in Google Scholar

6. Rischin D, Peters LJ, O’Sullivan B. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989-95.10.1200/JCO.2009.27.444920479425Search in Google Scholar

7. Di Silvestro PA, Ali S, Craighead PS. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32:458-64.10.1200/JCO.2013.51.4265391233024395863Search in Google Scholar

8. Chen HHW, Kuo MT. Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy. Metal-Based Drugs. 2010;2010:430939.Search in Google Scholar

9. Ozkan TA, Aydin U, Ay D, Cebeci IOO. Cisplatin and bleomycininduced acute peripheral-vascular stenosis in patient with testicular cancer. Urology Annals. 2016;8:483-5.10.4103/0974-7796.192096510015928057998Search in Google Scholar

10. Qian X, Ma C, Hoffmann TK, Kaufmann AM, Albers AE. Taxanecisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. SpringerPlus. 2015;4:208.10.1186/s40064-015-0988-5442282725977896Search in Google Scholar

11. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78.10.1016/j.ejphar.2014.07.025414668425058905Search in Google Scholar

12. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010;2:2490-518.10.3390/toxins2112490Search in Google Scholar

13. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin. Nephrol. 2003;23:460-4.Search in Google Scholar

14. Guise CP, Mowday AM, Ashoorzadeh A. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chinese Journal of Cancer. 2014;33(2):80-6.10.5732/cjc.012.10285Search in Google Scholar

15. Rades D, Seidl D, Janssen S, Strojan P, Karner K, Bajrovic A, Hakim SG. Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. European Archives of Oto-Rhino-Laryngology. 2017;1:1-7.10.1007/s00405-016-4326-5Search in Google Scholar

16. Rabik C, Fishel M, Holleran J, Kasza K, Kelley M, Egorin M, Dolan M. Enhancement of cisplatin cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 2008;327:442-52.Search in Google Scholar

17. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7): 495-504.10.1007/s00204-006-0173-2Search in Google Scholar

18. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol. 2004;23:29-34.10.1191/0960327104ht413oaSearch in Google Scholar

19. Delahoussaye YM, Evans JW, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol. 2001;62(9):1201-9.10.1016/S0006-2952(01)00784-5Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo